Its triple agonism allows simultaneous study of combined GLP-1 + GIP + glucagon effects, experimental dissections impossible with mono-agonists or dual agonists
Those who completed the full 48 weeks averaged significantly better outcomes than those who discontinued early, reinforcing the importance of persistence through the challenging adaptation period
We now understand obesity in a way that we didnt 10 or 20 years ago, and we know obesity is a metabolic disease
One of those researchers is Georgia State University Professor of Neuroscience and Georgia Research Alliance Distinguished Investigator Eric Krause
Week 4 involves evaluation and adjustment, reviewing the first month's experiences to identify what worked well and what challenges need addressing
In the SURMOUNT-1 clinical trial, patients achieved significant weight reduction over 72 weeks, with average losses ranging from 15% to 21% of initial body weight depending on the dose
